Professional Documents
Culture Documents
The World Health Organization (WHO) projected that, in 2005, chronic respiratory disease would be the
third-leading cause of deaths from chronic disease worldwide
Adapted from: World Health Organization. Preventing chronic diseases: a vital investment. (2005) Available at:
http://www.who.int/chp/chronic_disease_report/contents/en/index.html (accessed Mei 2015)
Riskesdas 2013
Differential Diagnosis
ASTHMA
COPD
Onset in mid-life
Symptoms slowly
progressive
Long smoking history
Asthma Triggers
COPD Facts
Assessment of COPD
(GOLD 2015)
1.
2.
Treatment issues
Check inhaler technique and adherence
Ask about side-effects
Does the patient have a written asthma
action plan?
What are the patients attitudes and goals
for their asthma?
3.
Comorbidities
Think of rhinosinusitis, GERD, obesity,
obstructive sleep apnea, depression,
anxiety
These may contribute to symptoms and
poor quality of life
STEP 5
STEP 4
Other
controller
options
Consider
low dose
ICS
RELIEVER
REMEMBER
TO...
STEP 2
STEP 3
Low dose
ICS/LABA*
Leukotriene receptor
antagonists (LTRA)
Low dose theophylline*
Med/high
ICS/LABA
Add tiotropium#
High dose ICS
+ LTRA
(or + theoph*)
As-needed SABA or
low dose ICS/formoterol**
PREFERRED
CONTROLLER
CHOICE
STEP 1
SEVERE
Talks in phrases
Prefers sitting to lying
Not agitated
Respiratory rate increased
Accessory muscles not used
Pulse rate 100120 bpm
O2 saturation (on air) 9095%
PEF >50% predicted or best
Talks in words
Sits hunched forwards
Agitated
Respiratory rate >30/min
Accessory muscles being used
Pulse rate >120 bpm
O2 saturation (on air) < 90%
PEF 50% predicted or best
Short-acting beta2-agonists
Consider ipratropium bromide
Controlled O2 to maintain
saturation 9395% (children 94-98%)
Oral corticosteroids
Short-acting beta2-agonists
Ipratropium bromide
Controlled O2 to maintain
saturation 9395% (children 94-98%)
Oral or IV corticosteroids
Consider IV magnesium
Consider high dose ICS
Adaptation from GINA 2015
Long-acting beta2-agonists
Anticholinergics
Short-acting anticholinergics ( misalnya Atrovent )
Long-acting anticholinergics
Phosphodiesterase-4 inhibitors
Adaptation from GOLD 2015
Mechanism of Action
Salbutamol
Sympathetic Way
2 Agonist
2
Reseptor
Ipratropium
Parasympathetic Way
Anti Cholinergic
Cholinergic
Reseptor
Device type
Nebulizers
Pressurized Metered-Dose Inhalers (pMDIs)
Dry-Powder Inhalers (DPIs)
Interface / Attachment
Mouthpieces
Facemasks
Spacers
Extension device
Holding chambers
Barry et al. Adv Drug Deliv Rev. 2003;55:879-923; Bisgaard et al. Chapter 12. Drug Delivery to the Lung. Marcel Dekker 2001;162:389-420.
>10m
7 - 10m
4 - 6m
2 - 3m
1m
<1m
No Deposition
low dose
directly to
resp system
minimal
side effects
high
th/. ratio
safety of
longterm use
fast onset
reliever
DBS 2004
controller
Garrett JE, Town GI, Rodwell P, Kelly AM. Nebulized Salbutamol with and without ipratropium bromide in the treatment of acute asthma, J Allergy Clin
Immunol 1997; 100(2): 165-170
77%
31%
Salbutamol
Combivent UDV
ODriscoll BR Nebulized Salbutamol with & without Ipratropium Bromide, Lancet 1989; 333 (8652): 1418-1420
40
30
Kombinasi UDV
Combivent
Salbutamol
20
10
0
0.25 0.5 0.75
1 - Nebulizer
Preparation of the device and the drug
Place the interface
Patient breath normally, sometimes with deep
breathing
Updated 2015
1.
2.
3.
4.
5.
SUMMARY
The goal of asthma and COPD treatment is to
improve the quality of life
ICS can be use for Asthma but not effective for COPD
Combivent UDV is better in terms of improving
lung function (FEV1) compared with salbutamol
alone in adult asthma patients
Combivent UDV is recomended in Local and
Internasional Guideline
Combivent UDV availables in JKN/BPJS